Cipla, which has long-standing experience in antibiotic development in India, strikes alliance with US firm SIGA Technologies. The partners are targeting novel antibacterials, especially against biothreats, and expect to cater to US agency BARDA, among others.
Cipla Limited is scaling up in the fight against antimicrobial resistance (AMR), a segment where it hopes to have a meaningful presence and deploy a range of innovative approaches.
Through its affiliate Cipla Therapeutics, the Indian company has struck an alliance with US commercial-stage pharma firm SIGA Technologies, Inc to provide “sustained innovation” and
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
